ArticleThe Lancet. Rheumatology2021

IL-1 and IL-6 inhibition affects the neutralising activity of anti-SARS-CoV-2 antibodies in patients with COVID-19.

Emanuel Della-Torre et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.